35 replace_table_token_8_th based on this analysis , we allocated $ 29.8 million to non-amortizable intangible assets and $ 1.7 million to amortizable intangible assets . we are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years . the weighted average remaining life for amortizable intangible assets at march 31 , 2014 was 14.5 years . we also recorded goodwill of $ 23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired . the full amount of goodwill is deductible for income tax purposes . the pro-forma effect of this acquisition on revenues and earnings was not material . acquisition of glaxosmithkline otc brands on december 20 , 2011 , we entered into two separate agreements with gsk to acquire a total of 17 north american otc healthcare brands for $ 660.0 million in cash ( the `` gsk agreement `` ) . on january 31 , 2012 , we completed , subject to a post-closing inventory and apportionment adjustment , as defined in the gsk agreement , the acquisition of the gsk brands i , including the related contracts , trademarks , and inventory for $ 615.0 million in cash . the gsk brands i include , among other brands , bc , goody 's and ecotrin brands of pain relievers ; beano , gaviscon , phazyme , tagamet and fiber choice gastrointestinal brands ; and the sominex sleep aid brand . on march 30 , 2012 , we completed , subject to a post-closing inventory and apportionment adjustment , as defined in the gsk agreement , the acquisition of the debrox and gly-oxide brands in the united states , including the related contracts , trademarks and inventory , for $ 45.0 million in cash . both the gsk brands i and gsk brands ii are complementary to our existing otc healthcare portfolio . these acquisitions were also accounted for in accordance with the business combinations topic of the fasb asc 805. the purchase price of the gsk brands i and gsk brands ii was funded by cash provided by the issuance of long-term debt and additional bank borrowings , which are discussed further in note 10 to the consolidated financial statements in this annual report on form 10-k. in april 2012 , we received the post-closing inventory and apportionment adjustments , attributable to both gsk brands i and gsk brands ii , which required us to pay an additional $ 2.8 million to gsk , and in may 2012 we received a revised post-closing inventory and apportionment adjustment , attributable to gsk brands ii , which required us to pay an additional $ 0.2 million , for a total of $ 3.0 million , to gsk . 36 concurrent with the closing of the gsk brands i transaction , we entered into a transitional services agreement with gsk ( the “ tsa ” ) , whereby gsk provided us with various services including marketing , operations , finance and other services from the gsk brands i acquisition date through june 30 , 2012 , with additional finance support through august 31 , 2012. as part of the tsa , gsk , among other things , shipped products , invoiced customers , collected from customers and paid certain vendors on our behalf . our initial costs under the tsa were approximately $ 2.5 million per month for the length of the agreement and were reduced during the service period as we removed certain services and transitioned those processes to us . we incurred $ 6.9 million in tsa costs for the year ended march 31 , 2013. pursuant to the tsa , we received on a monthly basis the amount owed to us for revenues and expenses , net of gsk 's tsa fees and inventory that gsk purchased on our behalf . the allocation of the purchase price to assets acquired is based on a valuation we performed to determine the fair value of such assets as of the acquisition date . the following table summarizes our allocation of the $ 663.0 million purchase price to the assets we acquired at the gsk brands i and gsk brands ii acquisition dates : replace_table_token_9_th transaction and other costs of $ 13.8 million associated with the gsk brands acquisition are included in general and administrative expenses in our consolidated statements of income and comprehensive income for 2012. we recorded goodwill based on the amount by which the purchase price exceeded the fair value of assets acquired . the amount of goodwill deductible for tax purposes is $ 20.2 million . the fair value of the trade names is comprised of $ 556.9 million of non-amortizable intangible assets and $ 67.2 million of amortizable intangible assets . we are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 19.3 years . the weighted average remaining life for amortizable intangible assets at march 31 , 2014 was 17.0 years . the operating results of the gsk brands i have been included in our consolidated financial statements from february 1 , 2012 , while the operating results of the gsk brands ii are included in our consolidated financial statements beginning april 1 , 2012. sale of the phazyme brand on october 31 , 2012 , we divested the phazyme gas treatment brand , which was a non-core otc brand that we acquired from gsk in january 2012. we received $ 21.7 million from the divestiture on october 31 , 2012 and the remaining $ 0.6 million on january 4 , 2013. the proceeds were used to repay debt . no significant gain or loss was recorded as a result of the sale . story_separator_special_tag as a result , any material changes to these assumptions could require us to record additional impairment in the future . the company has experienced revenue declines in regard to certain brands in its household cleaning segment during 2013 and 2012. adverse changes in the expected operating results and or unfavorable changes in other economic factors used to estimate fair values of these specific brands could result in a non-cash impairment charge in the future . goodwill as of march 31 , 2014 , we had 20 reporting units with goodwill , including six reporting units resulting from the acquisition of the gsk brands , and five reporting units resulting from the acquisition of the care pharma brands . as part of our annual test for impairment of goodwill , management estimates the discounted cash flows of each reporting unit , which is at the brand level , and one level below the operating segment level , to estimate their respective fair values . in performing this analysis , management considers the same types of information as listed below in regard to finite-lived intangible assets . future events , such as competition , technological advances and reductions in advertising support for our trademarks and trade names , could cause subsequent evaluations to utilize different assumptions . in the event that the carrying amount of the reporting unit exceeds the fair value , management would then be required to allocate the estimated fair value of the assets and liabilities of the reporting unit as if the unit was acquired in a business combination , thereby revaluing the carrying amount of goodwill . 41 indefinite-lived intangible assets at each reporting period , management analyzes current events and circumstances to determine whether the indefinite life classification for a trademark or trade name continues to be valid . if circumstances warrant a change to a finite life , the carrying value of the intangible asset would then be amortized prospectively over the estimated remaining useful life . management tests the indefinite-lived intangible assets for impairment by comparing the carrying value of the intangible asset to its estimated fair value . since quoted market prices are seldom available for trademarks and trade names such as ours , we utilize present value techniques to estimate fair value . accordingly , management 's projections are utilized to assimilate all of the facts , circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life . in performing this analysis , management considers the same types of information as listed below in regard to finite-lived intangible assets . in a manner similar to goodwill , future events , such as competition , technological advances and reductions in advertising support for our trademarks and trade names , could cause subsequent evaluations to utilize different assumptions . once that analysis is completed , a discount rate is applied to the cash flows to estimate fair value . finite-lived intangible assets as mentioned above , when events or changes in circumstances indicate the carrying value of the assets may not be recoverable , management performs a review to ascertain the impact of events and circumstances on the estimated useful lives and carrying values of our trademarks and trade names . in connection with this analysis , management : reviews period-to-period sales and profitability by brand ; analyzes industry trends and projects brand growth rates ; prepares annual sales forecasts ; evaluates advertising effectiveness ; analyzes gross margins ; reviews contractual benefits or limitations ; monitors competitors ' advertising spend and product innovation ; prepares projections to measure brand viability over the estimated useful life of the intangible asset ; and considers the regulatory environment , as well as industry litigation . if analysis of any of the aforementioned factors warrants a change in the estimated useful life of the intangible asset , management will reduce the estimated useful life and amortize the carrying value prospectively over the shorter remaining useful life . management 's projections are utilized to assimilate all of the facts , circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life . future events , such as competition , technological advances and reductions in advertising support for our trademarks and trade names , could cause subsequent evaluations to utilize different assumptions . in the event that the long-term projections indicate that the carrying value is in excess of the undiscounted cash flows expected to result from the use of the intangible assets , management is required to record an impairment charge . once that analysis is completed , a discount rate is applied to the cash flows to estimate fair value . the impairment charge is measured as the excess of the carrying amount of the intangible asset over fair value as calculated using the discounted cash flow analysis . impairment analysis we utilize the discounted cash flow method to estimate the fair value of our indefinite-lived intangible assets and goodwill and the undiscounted cash flow method to estimate the fair value of our finite-lived intangible assets . this methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently . in addition , we considered our market capitalization at march 31 , 2014 , as compared to the aggregate fair values of our reporting units , to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology . as a result of our analysis , we did not record an impairment charge in 2014. based on our analysis , the aggregate fair value exceeded the carrying value by 53.1 % . one individual reporting unit 's fair value exceeded its carrying value by less than 10.0 % . the reporting unit 's associated carrying value of goodwill and intangible assets amounted to $ 0.8 million at march 31 , 2014. additionally , certain brands

loss on extinguishment of debt on december 17 , 2013 , we offered to redeem the 2010 senior notes at a premium of 6.33 % , of which $ 201.7 million were redeemed on such date . the remaining $ 48.3 million were redeemed on january 16 , 2014. as a result , during the quarter ended december 31 , 2013 , we recorded a $ 15.0 million loss on the early extinguishment of debt relating to the $ 201.7 million 2010 senior notes redeemed and recorded an additional loss of $ 3.3 million on the remaining $ 48.3 million tendered on january 16 , 2014. the $ 18.3 million loss consists of premium payments of $ 15.5 million , write-off of deferred financing costs of $ 2.2 million , and write-off of debt discount of $ 0.6 million . income taxes the provision for income taxes during 2014 was $ 29.1 million versus $ 40.5 million in 2013. the effective tax rate on income before income taxes was 28.6 % during 2014 versus 38.2 % during 2013. the 2014 tax rate reflects the impact of non-deductible compensation of $ 1.0 million and a non-cash benefit of $ 8.9 million to adjust our current and deferred tax balances for lower state income taxes . this benefit was primarily related to a recent change in state law where we have our major distribution center that taxes earnings attributed to in-state revenues only . the 2013 tax rate reflects the impact of non-deductible compensation of $ 1.7 million and a non-cash benefit of $ 1.7 million for expected lower future state taxes .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```loss on extinguishment of debt on december 17 , 2013 , we offered to redeem the 2010 senior notes at a premium of 6.33 % , of which $ 201.7 million were redeemed on such date . the remaining $ 48.3 million were redeemed on january 16 , 2014. as a result , during the quarter ended december 31 , 2013 , we recorded a $ 15.0 million loss on the early extinguishment of debt relating to the $ 201.7 million 2010 senior notes redeemed and recorded an additional loss of $ 3.3 million on the remaining $ 48.3 million tendered on january 16 , 2014. the $ 18.3 million loss consists of premium payments of $ 15.5 million , write-off of deferred financing costs of $ 2.2 million , and write-off of debt discount of $ 0.6 million . income taxes the provision for income taxes during 2014 was $ 29.1 million versus $ 40.5 million in 2013. the effective tax rate on income before income taxes was 28.6 % during 2014 versus 38.2 % during 2013. the 2014 tax rate reflects the impact of non-deductible compensation of $ 1.0 million and a non-cash benefit of $ 8.9 million to adjust our current and deferred tax balances for lower state income taxes . this benefit was primarily related to a recent change in state law where we have our major distribution center that taxes earnings attributed to in-state revenues only . the 2013 tax rate reflects the impact of non-deductible compensation of $ 1.7 million and a non-cash benefit of $ 1.7 million for expected lower future state taxes .
```    
 Suspicious Activity Report : 35 replace_table_token_8_th based on this analysis , we allocated $ 29.8 million to non-amortizable intangible assets and $ 1.7 million to amortizable intangible assets . we are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years . the weighted average remaining life for amortizable intangible assets at march 31 , 2014 was 14.5 years . we also recorded goodwill of $ 23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired . the full amount of goodwill is deductible for income tax purposes . the pro-forma effect of this acquisition on revenues and earnings was not material . acquisition of glaxosmithkline otc brands on december 20 , 2011 , we entered into two separate agreements with gsk to acquire a total of 17 north american otc healthcare brands for $ 660.0 million in cash ( the `` gsk agreement `` ) . on january 31 , 2012 , we completed , subject to a post-closing inventory and apportionment adjustment , as defined in the gsk agreement , the acquisition of the gsk brands i , including the related contracts , trademarks , and inventory for $ 615.0 million in cash . the gsk brands i include , among other brands , bc , goody 's and ecotrin brands of pain relievers ; beano , gaviscon , phazyme , tagamet and fiber choice gastrointestinal brands ; and the sominex sleep aid brand . on march 30 , 2012 , we completed , subject to a post-closing inventory and apportionment adjustment , as defined in the gsk agreement , the acquisition of the debrox and gly-oxide brands in the united states , including the related contracts , trademarks and inventory , for $ 45.0 million in cash . both the gsk brands i and gsk brands ii are complementary to our existing otc healthcare portfolio . these acquisitions were also accounted for in accordance with the business combinations topic of the fasb asc 805. the purchase price of the gsk brands i and gsk brands ii was funded by cash provided by the issuance of long-term debt and additional bank borrowings , which are discussed further in note 10 to the consolidated financial statements in this annual report on form 10-k. in april 2012 , we received the post-closing inventory and apportionment adjustments , attributable to both gsk brands i and gsk brands ii , which required us to pay an additional $ 2.8 million to gsk , and in may 2012 we received a revised post-closing inventory and apportionment adjustment , attributable to gsk brands ii , which required us to pay an additional $ 0.2 million , for a total of $ 3.0 million , to gsk . 36 concurrent with the closing of the gsk brands i transaction , we entered into a transitional services agreement with gsk ( the “ tsa ” ) , whereby gsk provided us with various services including marketing , operations , finance and other services from the gsk brands i acquisition date through june 30 , 2012 , with additional finance support through august 31 , 2012. as part of the tsa , gsk , among other things , shipped products , invoiced customers , collected from customers and paid certain vendors on our behalf . our initial costs under the tsa were approximately $ 2.5 million per month for the length of the agreement and were reduced during the service period as we removed certain services and transitioned those processes to us . we incurred $ 6.9 million in tsa costs for the year ended march 31 , 2013. pursuant to the tsa , we received on a monthly basis the amount owed to us for revenues and expenses , net of gsk 's tsa fees and inventory that gsk purchased on our behalf . the allocation of the purchase price to assets acquired is based on a valuation we performed to determine the fair value of such assets as of the acquisition date . the following table summarizes our allocation of the $ 663.0 million purchase price to the assets we acquired at the gsk brands i and gsk brands ii acquisition dates : replace_table_token_9_th transaction and other costs of $ 13.8 million associated with the gsk brands acquisition are included in general and administrative expenses in our consolidated statements of income and comprehensive income for 2012. we recorded goodwill based on the amount by which the purchase price exceeded the fair value of assets acquired . the amount of goodwill deductible for tax purposes is $ 20.2 million . the fair value of the trade names is comprised of $ 556.9 million of non-amortizable intangible assets and $ 67.2 million of amortizable intangible assets . we are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 19.3 years . the weighted average remaining life for amortizable intangible assets at march 31 , 2014 was 17.0 years . the operating results of the gsk brands i have been included in our consolidated financial statements from february 1 , 2012 , while the operating results of the gsk brands ii are included in our consolidated financial statements beginning april 1 , 2012. sale of the phazyme brand on october 31 , 2012 , we divested the phazyme gas treatment brand , which was a non-core otc brand that we acquired from gsk in january 2012. we received $ 21.7 million from the divestiture on october 31 , 2012 and the remaining $ 0.6 million on january 4 , 2013. the proceeds were used to repay debt . no significant gain or loss was recorded as a result of the sale . story_separator_special_tag as a result , any material changes to these assumptions could require us to record additional impairment in the future . the company has experienced revenue declines in regard to certain brands in its household cleaning segment during 2013 and 2012. adverse changes in the expected operating results and or unfavorable changes in other economic factors used to estimate fair values of these specific brands could result in a non-cash impairment charge in the future . goodwill as of march 31 , 2014 , we had 20 reporting units with goodwill , including six reporting units resulting from the acquisition of the gsk brands , and five reporting units resulting from the acquisition of the care pharma brands . as part of our annual test for impairment of goodwill , management estimates the discounted cash flows of each reporting unit , which is at the brand level , and one level below the operating segment level , to estimate their respective fair values . in performing this analysis , management considers the same types of information as listed below in regard to finite-lived intangible assets . future events , such as competition , technological advances and reductions in advertising support for our trademarks and trade names , could cause subsequent evaluations to utilize different assumptions . in the event that the carrying amount of the reporting unit exceeds the fair value , management would then be required to allocate the estimated fair value of the assets and liabilities of the reporting unit as if the unit was acquired in a business combination , thereby revaluing the carrying amount of goodwill . 41 indefinite-lived intangible assets at each reporting period , management analyzes current events and circumstances to determine whether the indefinite life classification for a trademark or trade name continues to be valid . if circumstances warrant a change to a finite life , the carrying value of the intangible asset would then be amortized prospectively over the estimated remaining useful life . management tests the indefinite-lived intangible assets for impairment by comparing the carrying value of the intangible asset to its estimated fair value . since quoted market prices are seldom available for trademarks and trade names such as ours , we utilize present value techniques to estimate fair value . accordingly , management 's projections are utilized to assimilate all of the facts , circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life . in performing this analysis , management considers the same types of information as listed below in regard to finite-lived intangible assets . in a manner similar to goodwill , future events , such as competition , technological advances and reductions in advertising support for our trademarks and trade names , could cause subsequent evaluations to utilize different assumptions . once that analysis is completed , a discount rate is applied to the cash flows to estimate fair value . finite-lived intangible assets as mentioned above , when events or changes in circumstances indicate the carrying value of the assets may not be recoverable , management performs a review to ascertain the impact of events and circumstances on the estimated useful lives and carrying values of our trademarks and trade names . in connection with this analysis , management : reviews period-to-period sales and profitability by brand ; analyzes industry trends and projects brand growth rates ; prepares annual sales forecasts ; evaluates advertising effectiveness ; analyzes gross margins ; reviews contractual benefits or limitations ; monitors competitors ' advertising spend and product innovation ; prepares projections to measure brand viability over the estimated useful life of the intangible asset ; and considers the regulatory environment , as well as industry litigation . if analysis of any of the aforementioned factors warrants a change in the estimated useful life of the intangible asset , management will reduce the estimated useful life and amortize the carrying value prospectively over the shorter remaining useful life . management 's projections are utilized to assimilate all of the facts , circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life . future events , such as competition , technological advances and reductions in advertising support for our trademarks and trade names , could cause subsequent evaluations to utilize different assumptions . in the event that the long-term projections indicate that the carrying value is in excess of the undiscounted cash flows expected to result from the use of the intangible assets , management is required to record an impairment charge . once that analysis is completed , a discount rate is applied to the cash flows to estimate fair value . the impairment charge is measured as the excess of the carrying amount of the intangible asset over fair value as calculated using the discounted cash flow analysis . impairment analysis we utilize the discounted cash flow method to estimate the fair value of our indefinite-lived intangible assets and goodwill and the undiscounted cash flow method to estimate the fair value of our finite-lived intangible assets . this methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently . in addition , we considered our market capitalization at march 31 , 2014 , as compared to the aggregate fair values of our reporting units , to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology . as a result of our analysis , we did not record an impairment charge in 2014. based on our analysis , the aggregate fair value exceeded the carrying value by 53.1 % . one individual reporting unit 's fair value exceeded its carrying value by less than 10.0 % . the reporting unit 's associated carrying value of goodwill and intangible assets amounted to $ 0.8 million at march 31 , 2014. additionally , certain brands

